NASDAQ, RGEN - Repligen Corp
The following discussion of our business contains forward-looking statements
that involve risks and uncertainties. When used in this report, the words
?intend,? ?anticipate,? ?believe,? ?estimate,? ?plan? and ?expect? and similar
expressions as they relate to us are included to identify forward-looking
statements. Our actual results could differ materially from those anticipated in
these forward-looking statements and are a result of certain factors, including
those set forth under ?Risk Factors? and elsewhere in this Annual Report on Form
10-K.
Repligen Corporation (?Repligen,? the ?Company? or ?we?) is developing novel
therapeutics for the treatment of diseases of the central nervous system. We
also own intellectual property on two biological therapies which may provide
future revenues to support our product development efforts in neurological
diseases. ...
Read SEC Filing on NASDAQ.com »